Clinical trials: Liver and Intrahepatic Biliary Tract Cancer
Primary Liver Cancer, Metastatic Liver Cancer From Any Cancer Site
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
This study is a research and development initiative established to explore the use of magnetic resonance imaging (MRI) as a tool for managing organ motion of the liver in cancer patients planning procedures for stereotactic body…
- Trial name
- NCT02722395
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Duke University
Hepatocellular Carcinoma
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
- Trial name
- EMERALD-2 (NCT03847428)
- Testing
- Durvalumab, Bevacizumab
- Where
- 217 sites in United States, Australia and 22 more
- Volunteers
- 908 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Abstract of Research Proposal Radiofrequency ablation (RFA) has been proved to be a curative treatment with minimal invasiveness and high efficacy for small hepatocellular carcinoma (HCC) that is generally defined as maximal…
- Trial name
- NCT01858207
- Testing
- Transcatheter Arterial Chemoembolization, Radiofrequency ablation, Doxorubicin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Shi-Ming Lin
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03684811
- Testing
- FT-2102, Azacitidine, Nivolumab
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- Forma Therapeutics, Inc.
Pancreatic Cancer, Gastric Cancer
RCT of Mobile Apps & FitBit v. Usual Care
This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.
- Conditions
- Pancreatic Cancer, Gastric Cancer, Hepatic Cancer, Colon Cancer
- Trial name
- NCT03623464
- Testing
- Mobile health application and Fitbit + standard of care, Standard of care
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Weill Medical College of Cornell University
Liver Cancer, Hepatocellular Carcinoma
Pressure-enabled Delivery in Radioembolization (TriNav Study)
The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer
- Trial name
- PEDIR (NCT05128032)
- Testing
- Standard microcatheter, PEDD device
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
- Trial name
- EMERALD-3 (NCT05301842)
- Testing
- Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE)
- Where
- 171 sites in United States, Belgium and 20 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer.
- Conditions
- PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
- Trial name
- NCT00980460
- Testing
- Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride
- Where
- 209 sites in United States, Australia and 4 more
- Volunteers
- 236 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer).
- Trial name
- NCT00057382
- Testing
- T138067 intravenous, doxorubicin intravenous
- Where
- 76 sites in United States, Brazil and 9 more
- Volunteers
- 750 people
- Sponsor
- Tularik
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Hepatocellular Carcinoma
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This clinical trial studies sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Sorafenib tosylate may block some of the enzymes needed for tumor cell growth.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Hepatocellular Carcinoma, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma
- Trial name
- NCT02072486
- Testing
- Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Sarcoma
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving…
- Conditions
- Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer
- Trial name
- NCT07447050
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Irvine
Unresectable Hepatocellular Carcinoma
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care.
- Trial name
- NCT03107416
- Testing
- Hepatic artery embolization (HAE), Bumetanide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Liver Cancer
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
Capecitabine is a chemotherapeutic that has been approved for use in breast and colorectal cancers. The advantages of capecitabine are that (1) it is an oral drug; and (2) it is less toxic than many other chemotherapeutics.
- Trial name
- NCT00076609
- Testing
- PHY906, capecitabine
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- PhytoCeutica
Liver Cancer, Hepatobiliary Tract Adenomas and Carcinomas
Observational Study of Biomarker During Liver Surgery
The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver…
- Trial name
- NCT02102971
- Testing
- Hepatocellular carcinoma
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Florida
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Hepatocellular Carcinoma (HCC), Solid Tumors
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Researchers are studying a new potential treatment for liver cancer or other select solid cancers. To do this, researchers have developed a protein, called a monoclonal antibody, which can find and attach itself to another…
- Trial name
- NCT06345001
- Testing
- BAY3630942, BAY3547922
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver
Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer
Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic…
- Trial name
- CHAMAD (NCT07145385)
- Testing
- multiplex digital PCR
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Cancer of Kidney and Renal Pelvis, Cancer of Liver
Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
The purpose of he study is to evaluate effects of dexmedetomidine on pain during radiofrequency ablation of liver and kidney tumours.
- Trial name
- NCT02016391
- Testing
- Dexmedetomidine
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Uppsala University Hospital
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.